Should Empiric Anti-Fungals Be Administered Routinely for All Patients with Perforated Peptic Ulcers? A Critical...

Area of Science:

• Gastroenterology
• Surgical Infections
• Critical Care Medicine

Background:

• Perforated peptic ulcers (PPUs) are surgical emergencies with high mortality, leading to secondary peritonitis from microbial contamination.
• Surgery is the primary treatment, but patient comorbidities significantly affect outcomes, necessitating continued resuscitation and antimicrobial therapy.

Purpose of the Study:

• To review the existing literature on the role and efficacy of empiric antifungal treatment in patients with perforated peptic ulcers.
• To identify gaps in evidence and guide future research directions regarding antifungal use in PPUs.

Main Methods:

• A literature review was conducted to analyze studies evaluating empiric antifungal use in perforated peptic ulcers.
• Studies were assessed for heterogeneity in patient demographics, surgical pathology, antifungal agents, and treatment timing.

Main Results:

• A paucity of studies exists regarding empiric antifungals in PPUs, with conflicting results.
• Significant heterogeneity was observed across studies, complicating definitive conclusions on antifungal efficacy.
• Differentiating fungal colonization from invasive fungal infection is crucial for appropriate antifungal administration.

Conclusions:

• The role of empiric antifungal treatment in perforated peptic ulcers remains unclear due to limited and conflicting evidence.
• Clinical judgment, supported by potential biomarkers and multidisciplinary discussion, is essential for guiding antifungal therapy.
• Further research is required to identify specific patient populations who may benefit from empiric antifungal use.